Your browser doesn't support javascript.
loading
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona, Andrés F; Ruiz-Patiño, Alejandro; Recondo, Gonzalo; Martín, Claudio; Raez, Luis; Samtani, Suraj; Minata, José Nicolas; Blaquier, Juan Bautista; Enrico, Diego; Burotto, Mauricio; Ordóñez-Reyes, Camila; Chamorro, Diego F; Garcia-Robledo, Juan Esteban; Corrales, Luis; Zatarain-Barrón, Zyanya Lucia; Más, Luis; Sotelo, Carolina; Ricaurte, Luisa; Santoyo, Nicolas; Cuello, Mauricio; Mejía, Sergio; Jaller, Elvira; Vargas, Carlos; Carranza, Hernán; Otero, Jorge; Rodríguez, July; Archila, Pilar; Bermudez, Maritza; Gamez, Tatiana; Cordeiro de Lima, Vladmir; Freitas, Helano; Russo, Alessandro; Polo, Carolina; Malapelle, Umberto; Perez, Diego de Miguel; Rolfo, Christian; Viola, Lucia; Rosell, Rafael; Arrieta, Oscar.
Afiliação
  • Cardona AF; Direction of Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bo
  • Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Recondo G; Thoracic Oncology Section, Centro de Educación Médica e Investigaciones Clínicas - CEMIC, Buenos Aires, Argentina.
  • Martín C; Medical Oncology Department, Thoracic Oncology Section, Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Raez L; Thoracic Oncology Department, Memorial Cancer Institute, Memorial Health Care System, Miami, FL.
  • Samtani S; Medical Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile.
  • Minata JN; Medical Oncology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Blaquier JB; Medical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas - CEMIC, Buenos Aires, Argentina.
  • Enrico D; Medical Oncology Department, Thoracic Oncology Section, Instituto Alexander Fleming, Buenos Aires, Argentina.
  • Burotto M; Medical Oncology Department, Bradfordhill Institute, Santiago, Chile.
  • Ordóñez-Reyes C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Chamorro DF; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Garcia-Robledo JE; Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
  • Corrales L; Clinical Oncology Department, Oncology Unit, Hospital San Juan de Dios/Centro de Investigación y Manejo del Cáncer (CIMCA), San José, Costa Rica.
  • Zatarain-Barrón ZL; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City México.
  • Más L; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas - INEN, Lima, Perú.
  • Sotelo C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Ricaurte L; Pathology Department, Mayo Clinic, Rochester, MN.
  • Santoyo N; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Cuello M; Clinical Oncology Department, Hospital de Clinicas, Universidad de la Republica - UdeLAR, Montevideo, Uruguay.
  • Mejía S; Cancer Institute, Las Americas Clinic, Medellin, Colombia.
  • Jaller E; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Vargas C; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia; Clinical Oncology Department, Clínica del Country, Bogotá, Colombia.
  • Carranza H; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia; Clinical Oncology Department, Clínica del Country, Bogotá, Colombia.
  • Otero J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia; Clinical Oncology Department, Clínica del Country, Bogotá, Colombia.
  • Rodríguez J; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Bermudez M; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Gamez T; Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia; Molecular Oncology and Biology Systems Research Group (Fox-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.
  • Cordeiro de Lima V; Medical Oncology Department, A.C.Camargo Cancer Center, Sao Paulo, Brazil.
  • Freitas H; Medical Oncology Department, A.C.Camargo Cancer Center, Sao Paulo, Brazil.
  • Russo A; Medical Oncology Unit, A.O. Papardo, Messina, Italy.
  • Polo C; Clinical Oncology Department, Instituto Nacional de Cancerología - INC, Bogotá, Colombia.
  • Malapelle U; Department of Public Health, University Federico II, Naples, Italy.
  • Perez DM; Center for Thoracic Oncology, The Tisch Cancer Institute Icahn School of Medicine, Mount Sinai, Mount Sinai Health System, One Gustave Levy Place, NY.
  • Rolfo C; Center for Thoracic Oncology, The Tisch Cancer Institute Icahn School of Medicine, Mount Sinai, Mount Sinai Health System, One Gustave Levy Place, NY.
  • Viola L; Thoracic Oncology Unit, Fundación Neumológica Colombiana, Bogotá, Colombia.
  • Rosell R; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Barcelona, Spain.
  • Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City México.
Clin Lung Cancer ; 23(6): 522-531, 2022 09.
Article em En | MEDLINE | ID: mdl-35798634
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Middle aged Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Middle aged Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article